Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib

References

• DrukerBJGuilhotFO’BrienSGFive-year follow-up of patients receiving imatinib for chronic myeloid leukemiaN Engl J Med2006355232408241717151364
   PubMed Web of Science ®Google Scholar
• HochhausADrukerBSawyersCFavorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatmentBlood200811131039104317932248
   PubMed Web of Science ®Google Scholar
• MauroMJDefining and managing imatinib resistanceHematology Am Soc Hematol Educ Program200621922517124064
   PubMedGoogle Scholar
• MartinGSThe road to SrcOncogene200423487910791715489909
   PubMed Web of Science ®Google Scholar
• DorseyJFJoveRKrakerAJWuJThe pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cellsCancer Res200060123127313110866298
   PubMed Web of Science ®Google Scholar
• La RoseePCorbinASStoffregenEPDeiningerMWDrukerBJActivity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571)Cancer Res200262247149715312499247
   PubMed Web of Science ®Google Scholar
• GolasJMArndtKEtienneCSKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude miceCancer Res200363237538112543790
   PubMed Web of Science ®Google Scholar
• WarmuthMSimonNMitinaODual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinasesBlood2003101266467212393636
   PubMed Web of Science ®Google Scholar
• ShahNPTranCLeeFYChenPNorrisDSawyersCLOverriding imatinib resistance with a novel ABL kinase inhibitorScience2004305568239940115256671
   PubMed Web of Science ®Google Scholar
• O’HareTPollockRStoffregenEPInhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CMLBlood200410482532253915256422
   PubMed Web of Science ®Google Scholar
• LombardoLJLeeFYChenPDiscovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assaysJ Med Chem200447276658666115615512
   PubMed Web of Science ®Google Scholar
• RixUHantschelODurnbergerGChemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targetsBlood2007110124055406317720881
   PubMed Web of Science ®Google Scholar
• O’HareTWaltersDKStoffregenEPIn vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutantsCancer Res200565114500450515930265
   PubMed Web of Science ®Google Scholar
• TalpazMShahNPKantarjianHDasatinib in imatinib-resistant Philadelphia chromosome-positive leukemiasN Engl J Med2006354242531254116775234
   PubMed Web of Science ®Google Scholar
• HochhausABaccaraniMDeiningerMDasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibLeukemia20082261200120618401416
   PubMed Web of Science ®Google Scholar
• GuilhotFApperleyJKimDWDasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phaseBlood2007109104143415017264298
   PubMed Web of Science ®Google Scholar
• CortesJKimDWRaffouxEEfficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phaseLeukemia200822122176218318754032
   PubMed Web of Science ®Google Scholar
• TalpazMSilverRTDrukerBJImatinib induces durable hemato-logic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyBlood20029961928193711877262
   PubMed Web of Science ®Google Scholar
• SawyersCLHochhausAFeldmanEImatinib induces hematologic and cytogenetic responses in patients with chronic myelog-enous leukemia in myeloid blast crisis: results of a phase II studyBlood200299103530353911986204
   PubMed Web of Science ®Google Scholar
• KantarjianHMGilesFBhallaKNNilotinib in chronic myeloid leukemia patients in chronic phase (CMLCP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 studyASH Annual Meeting Abstracts2008112113238
   Google Scholar
• le CoutrePDGilesFHochhausANilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 studyASH Annual Meeting Abstracts2008112113229
   Google Scholar
• GilesFJLarsonRAKantarjianHMNilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinibJ Clin Oncol (Meeting Abstracts)20082615_suppl7017
   Web of Science ®Google Scholar
• CortesJKantarjianHMKimDEfficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinibASH Annual Meeting Abstracts2008112111098
   Google Scholar
• PasseriniCGPoglianiEMBaccaraniMBosutinib (SKI-606) demonstrates clinical activity and is well tolerated in patients with AP and BP CML and Ph+ ALLASH Annual Meeting Abstracts2008112111101
   Google Scholar
• LuoFRYangZCamusoADasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposureClin Cancer Res200612237180718617145844
   PubMed Web of Science ®Google Scholar
• ShahNPKantarjianHMKimDWIntermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemiaJ Clin Oncol200826193204321218541900
   PubMed Web of Science ®Google Scholar
• ShahNPKimDWKantarjianHMDasatinib Dose-Optimization in Chronic Phase Chronic Myeloid Leukemia (CML-CP): Two-year data from CA180-034 show equivalent long-term efficacy and improved safety with 100 mg once daily doseASH Annual Meeting Abstracts2008112113225
   Google Scholar
• ShahNPKasapCWeierCTransient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosisCancer Cell200814648549319061839
   PubMed Web of Science ®Google Scholar
• KantarjianHMKimDWDorlhiac-LlacerPDasatinib 140 mg once daily (QD) demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with accelerated phase chronic myeloid leukemia (CML-AP): 2-year follow-up data from CA180–035ASH Annual Meeting Abstracts2008112113224
   Google Scholar
• SaglioGKantarjianHMHochhausADasatinib 140 mg once daily (QD) demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with chronic myeloid leukemia in blast phase (CML-BP): 2-year data from CA180-035ASH Annual Meeting Abstracts2008112113226
   Google Scholar
• MullerMCCortesJKimDWDasatinib efficacy in patients with chronic myeloid leukemia in chronic phase (CML-CP) and pre-existing BCR-ABL mutationsASH Annual Meeting Abstracts200811211449
   Google Scholar
• MilojkovicDBuaMApperleyJFPrediction of cytogenetic response to second generation TKI therapy in CML chronic phase patients who have failed imatinib therapy and early identification of factors that influence survivalASH Annual Meeting Abstracts200811211332
   Google Scholar
• TamCSKantarjianHGarcia-ManeroGFailure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemiaBlood2008112351651818492956
   PubMed Web of Science ®Google Scholar
• BranfordSLawrenceRFletcherLFieldCRudzkiZHughesTThe initial molecular response of chronic phase CML patients treated with second generation ABL inhibitor therapy after imatinib failure can predict inadequate response and provide indications for rational mutation screeningASH Annual Meeting Abstracts200811211331
   Google Scholar
• BranfordSCrossNCHochhausARationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemiaLeukemia200620111925193016990771
   PubMed Web of Science ®Google Scholar
• BaccaraniMRostiGSaglioGDasatinib time to and durability of major and complete cytogenetic response (MCyR and CCyR) in patients with chronic myeloid leukemia in chronic phase (CML-CP)ASH Annual Meeting Abstracts200811211450
   Google Scholar
• HochhausAMullerMCRadichJDasatinib-associated major molecular responses are rapidly achieved in patients with chronic myeloid leukemia in chronic phase (CML-CP) following resistance, suboptimal response, or intolerance on imatinibASH Annual Meeting Abstracts2008112111095
   Google Scholar
• TakayamaNSatoNO’BrienSGIkedaYOkamotoSImatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluidBr J Haematol2002119110610812358909
   PubMed Web of Science ®Google Scholar
• PfeiferHWassmannBHofmannWKRisk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylateClin Cancer Res20039134674468114581336
   PubMed Web of Science ®Google Scholar
• BujassoumSRifkindJLiptonJHIsolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapyLeuk Lymphoma200445240140315101732
   PubMed Web of Science ®Google Scholar
• LeisJFStepanDECurtinPTCentral nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571)Leuk Lymphoma200445469569815160941
   PubMed Web of Science ®Google Scholar
• MatsudaMMoritaYShimadaTExtramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylateInt J Hematol200581430730915914360
   PubMed Web of Science ®Google Scholar
• AbdelhalimABarcosMBlockAWRemission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapyLeuk Lymphoma20074851053105617487757
   PubMed Web of Science ®Google Scholar
• PorkkaKKoskenvesaPLundanTDasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemiaBlood200811241005101218477770
   PubMed Web of Science ®Google Scholar
• ZwaanCMRizzariCvan der VeldenVHJDasatinib in children and adolescents with relapsed or refractory leukemia: interim results of the CA180-018 phase i study from the ITCC consortiumASH Annual Meeting Abstracts2008112113241
   Google Scholar
• Quintas-CardamaAKantarjianHMNicaiseCCytopenias in patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP) treated with dasatinib (SPRYCEL(R)): clinical features and management, including outcome after hematopoietic growth factor therapyASH Annual Meeting Abstracts2006108112163
   Google Scholar
• PorkkaKKhouryHJPaquetteRDasatinib 100 mg once daily (QD) maintains long-term efficacy and minimizes the occurrence of pleural effusion: an analysis of 24-month data in patients with resistance, suboptimal response, or intolerance to imatinib (CA180-034)ASH Annual Meeting Abstracts2008112113242
   Google Scholar
• Quintas-CardamaAKantarjianHO’BrienSPleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failureJ Clin Oncol200725253908391417761974
   PubMed Web of Science ®Google Scholar
• BergeronAReaDLevyVLung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case seriesAm J Respir Crit Care Med2007176881481817600277
   PubMed Web of Science ®Google Scholar
• de LavalladeHPunnialingamSMilojkovicDPleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesisBr J Haematol2008141574574718331365
   PubMed Web of Science ®Google Scholar
• LindahlPJohanssonBRLeveenPBetsholtzCPericyte loss and microaneurysm formation in PDGF-B-deficient miceScience199727753232422459211853
   PubMed Web of Science ®Google Scholar
• SchadeAESchievenGLTownsendRDasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferationBlood200811131366137717962511
   PubMed Web of Science ®Google Scholar
• BlakeSJBruceLAFraserCKHayballJDHughesTPDasatinib suppresses in vitro natural killer cell cytotoxicityBlood200811184415441618398058
   PubMed Web of Science ®Google Scholar
• BlakeSHughesTPMayrhoferGLyonsABThe Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitroClin Immunol2008127333033918395492
   PubMed Web of Science ®Google Scholar
• ReaDBergeronAFieschiCBengoufaDOksenhendlerEDombretHDasatinib-induced lupusLancet2008372964071371418761212
   PubMed Web of Science ®Google Scholar
• KimDHKamel-ReidSChangHNatural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemiaHaematologica200994113513919066329
   PubMed Web of Science ®Google Scholar
• MustjokiSEkblomMArstilaTPClonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapyASH Annual Meeting Abstracts200811211573
   Google Scholar
• MahonFXDeiningerMWSchultheisBSelection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistanceBlood20009631070107910910924
   PubMed Web of Science ®Google Scholar
• GorreMEMohammedMEllwoodKClinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplificationScience2001293553187688011423618
   PubMed Web of Science ®Google Scholar
• BranfordSRudzkiZWalshSHigh frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistanceBlood20029993472347511964322
   PubMed Web of Science ®Google Scholar
• ShahNPNicollJMNagarBMultiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemiaCancer Cell20022211712204532
   PubMed Web of Science ®Google Scholar
• von BubnoffNSchnellerFPeschelCDuysterJBCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective studyLancet2002359930548749111853795
   PubMed Web of Science ®Google Scholar
• le CoutrePTassiEVarella-GarciaMInduction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplificationBlood20009551758176610688835
   PubMed Web of Science ®Google Scholar
• JordanidesNEJorgensenHGHolyoakeTLMountfordJCFunctional ABCG2 is over-expressed on primary CML CD34+ cells and is inhibited by imatinib mesylateBlood200610841370137316627755
   PubMed Web of Science ®Google Scholar
• ThomasJWangLClarkREPirmohamedMActive transport of imatinib into and out of cells: implications for drug resistanceBlood2004104123739374515315971
   PubMed Web of Science ®Google Scholar
• WhiteDLSaundersVADangPOCT-1 mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107); reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinibBlood2006108269770416597591
   PubMed Web of Science ®Google Scholar
• DonatoNJWuJYStapleyJBCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571Blood2003101269069812509383
   PubMed Web of Science ®Google Scholar
• ShahNPSawyersCLMechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemiasOncogene200322477389739514576846
   PubMed Web of Science ®Google Scholar
• TokarskiJSNewittJAChangCYThe structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutantsCancer Res200666115790579716740718
   PubMed Web of Science ®Google Scholar
• SoveriniSColarossiSGnaniAResistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domainHaematologica200792340140417339191
   PubMed Web of Science ®Google Scholar
• BradeenHAEideCAO’HareTComparison of imatinib, dasatinib (BMS-354825), and nilotinib (AMN107) in an n-ethyl-n-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinationsBlood200610872332233816772610
   PubMed Web of Science ®Google Scholar
• BurgessMRSkaggsBJShahNPLeeFYSawyersCLComparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistanceProc Natl Acad Sci U S A200510293395340015705718
   PubMed Web of Science ®Google Scholar
• ShahNPSkaggsBJBranfordSSequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potencyJ Clin Invest200711792562256917710227
   PubMed Web of Science ®Google Scholar
• CortesJJabbourEKantarjianHDynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitorsBlood2007110124005401117785585
   PubMed Web of Science ®Google Scholar
• KhorashadJSMilojkovicDMehtaPIn vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinibBlood200811142378238117982022
   PubMed Web of Science ®Google Scholar
• JabbourEKantarjianHMJonesDCharacteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitorsBlood2008112134839484218818391
   PubMed Web of Science ®Google Scholar
• JabbourEKantarjianHMJonesDBurtonECortesJClinical characteristics and outcome of patients (pts) with V299L BCRABL kinase domain (KD) mutation after therapy with tyrosine kinase inhibitors (TKIs)ASH Annual Meeting Abstracts2008112111105
   Google Scholar
• O’HareTEideCATynerJWSGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinibProc Natl Acad Sci U S A2008105145507551218367669
   PubMed Web of Science ®Google Scholar
• GottesmanMMFojoTBatesSEMultidrug resistance in cancer: role of ATP-dependent transportersNat Rev Cancer200221485811902585
   PubMed Web of Science ®Google Scholar
• HegedusTOrfiLSeprodiAVaradiASarkadiBKeriGInteraction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1Biochim Biophys Acta200215872–331832512084474
   PubMed Web of Science ®Google Scholar
• WidmerNColomboSBuclinTDecosterdLAFunctional consequence of MDR1 expression on imatinib intracellular concentrationsBlood20031023114212869489
   PubMed Web of Science ®Google Scholar
• IllmerTSchaichMPlatzbeckerUP-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylateLeukemia200418340140814724652
   PubMed Web of Science ®Google Scholar
• BurgerHvan TolHBoersmaAWImatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pumpBlood200410492940294215251980
   PubMed Web of Science ®Google Scholar
• BurgerHvan TolHBrokMChronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumpsCancer Biol Ther20054774775215970668
   PubMed Web of Science ®Google Scholar
• HiwaseDKSaundersVHewettDDasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implicationsClin Cancer Res200814123881388818559609
   PubMed Web of Science ®Google Scholar
• GiannoudisADaviesALucasCMHarrisRJPirmohamedMClarkREEffective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemiaBlood200811283348335418669873
   PubMed Web of Science ®Google Scholar
• GrahamSMJorgensenHGAllanEPrimitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitroBlood200299131932511756187
   PubMed Web of Science ®Google Scholar
• CoplandMHamiltonAElrickLJDasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fractionBlood2006107114532453916469872
   PubMed Web of Science ®Google Scholar
• CoplandMPellicanoFRichmondLBMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitorsBlood200811152843285318156496
   PubMed Web of Science ®Google Scholar
• O’BrienSGGuilhotFLarsonRAImatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaN Engl J Med200334811994100412637609
   PubMed Web of Science ®Google Scholar
• HochhausAKantarjianHMBaccaraniMDasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapyBlood200710962303230917138817
   PubMed Web of Science ®Google Scholar